You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

PD-1, neoadjuvant therapy, radiotherapy

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

HNSCC, Radiotherapy, PD-1 Trial in Guangzhou (PD-1inhibitor, concurrent chemoradiotherapy)

Recruiting
  • HNSCC
  • +2 more
  • Guangzhou, Guangdong, China
    Sun yat-sen memorial hospital
Aug 6, 2023

Rectal Cancer Trial (Short-course radiotherapy combined with furoquintinib and PD-1 mAb)

Not yet recruiting
  • Rectal Cancer
  • Short-course radiotherapy combined with furoquintinib and PD-1 monoclonal antibody
  • (no location specified)
Aug 29, 2023

Locally Advanced Hypopharyngeal Carcinoma Trial in Shanghai (drug, procedure, radiation)

Not yet recruiting
  • Locally Advanced Hypopharyngeal Carcinoma
  • three cycles (toripalimab + cetuximab + platinum)
  • +2 more
  • Shanghai, Shanghai, China
    Eye & ENT Hospital of Fudan University
Nov 22, 2023

Head and Neck Squamous Cell Carcinoma, Neoadjuvant Therapy Trial in Wuhan (drug, procedure, radiation)

Not yet recruiting
  • Head and Neck Squamous Cell Carcinoma
  • Neoadjuvant Therapy
  • 3cycles (Toripalimab + cetuximab)
  • +2 more
  • Wuhan, Hebei, China
    Union Hospital, Tongji Medical College, Huazhong University of S
Aug 6, 2023

Preoperative Neoadjuvant Chemoradiotherapy Combined PD-1

Recruiting
  • Colorectal Neoplasms
  • long course radiotherapy + capecitabine + PD-1 monoclonal antibody
  • Beijing, Beijing, China
    Beijing Friendship Hospital
May 5, 2022

Advanced Esophageal Squamous Cell Cancer Trial in Jinan (Tislelizumab Combined With Neoadjuvant Radiotherapy and Chemotherapy)

Recruiting
  • Advanced Esophageal Squamous Cell Cancer
  • Tislelizumab Combined With Neoadjuvant Radiotherapy and Chemotherapy
  • Jinan, Shandong, China
    Shandong Cancer Hospital and Institute
Apr 11, 2022

Liver Cancer, Liver Transplant; Complications, Hepatocellular Carcinoma Trial in Shanghai (radiation, combination product, drug)

Not yet recruiting
  • Liver Cancer
  • +4 more
  • intensity-modulated radiotherapy
  • +5 more
  • Shanghai, China
    Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong Universi
Apr 20, 2022

Gastric or Gastroesophageal Junction Adenocarcinoma Trial in Nanjing (neoadjuvant chemo-hypofractionated radiotherapy plus PD-1

Active, not recruiting
  • Gastric or Gastroesophageal Junction Adenocarcinoma
  • neoadjuvant chemo-hypofractionated radiotherapy plus PD-1 antibody (Tislelizumab)
  • Nanjing, Jiangsu, China
    Jiangsu Cancer Hospital
Jul 4, 2023

Esophageal Squamous Cell Carcinoma Trial in Beijing (Durvalumab, Carboplatin, Paclitaxel)

Recruiting
  • Esophageal Squamous Cell Carcinoma
  • Beijing, Beijing, China
    Peking Union Medical College Hospital
Mar 12, 2022

Colorectal Cancer Trial (Serplulimab + FOLFOXIRI, Radiation therapy)

Not yet recruiting
  • Colorectal Cancer
  • Serplulimab + FOLFOXIRI
  • Radiation therapy
  • (no location specified)
Oct 24, 2023

Rectal Tumors Trial in Nanning (Tislelizumab, Capecitabine, Oxaliplatin)

Recruiting
  • Rectal Neoplasms
  • Nanning, Guangxi, China
    First Affiliated Hospital of Guangxi Medical University
Aug 27, 2023

Neoadjuvant Chemo, PD-1 Antibody, Radiotherapy Trial (neoadjuvant chemo combined with PD-1 antibody + radical radiotherapy)

Not yet recruiting
  • Neoadjuvant Chemotherapy
  • +3 more
  • neoadjuvant chemotherapy combined with PD-1 antibody + radical radiotherapy
  • (no location specified)
Sep 21, 2022

MSS, Rectal Cancer Trial (Sintilimab with Interleukin-2)

Not yet recruiting
  • MSS
  • Rectal Cancer
  • Sintilimab with Interleukin-2
  • (no location specified)
Nov 1, 2023

Early Low Rectal Cancer Trial in Shanghai (PD-1 antibody, Capecitabine, Oxaliplatin)

Recruiting
  • Early Low Rectal Cancer
  • PD-1 antibody
  • +3 more
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Jan 9, 2023

Locally Advanced Rectal Cancer Trial in Beijing (capecitabine, tislelizumab, thymalfasin)

Not yet recruiting
  • Locally Advanced Rectal Cancer
  • Beijing, China
  • +1 more
Sep 21, 2023

Multiple Cancer, Colorectal Cancer Trial (MSI-H/MSS (dMMR/pMMR) mixed sMPCC: combination of mFOLFOX6+PD-1 mAb neoadjuvant

Not yet recruiting
  • Multiple Cancer
  • Colorectal Cancer
  • MSI-H/MSS (dMMR/pMMR) mixed sMPCC: combination of mFOLFOX6+PD-1 monoclonal antibody neoadjuvant therapy
  • All-MSI-H (dMMR) sMPCC: single-drug PD-1 monoclonal antibody neoadjuvant therapy
  • (no location specified)
Aug 20, 2023

Rectal Tumors Malignant, Radiotherapy Trial in Beijing, Shenzhen (drug, radiation, combination product)

Not yet recruiting
  • Rectal Neoplasms Malignant
  • Radiotherapy
  • Beijing, Beijing, China
  • +1 more
Jul 29, 2022

Oral Squamous Cell Carcinoma, Neoadjvant Therapy, Anti-PD-1 Trial in Shanghai (Camrelizumab (anti-PD-1 inhibitor), Apatinib

Recruiting
  • Oral Squamous Cell Carcinoma
  • +3 more
  • Camrelizumab (anti-PD-1 inhibitor)
  • Apatinib (anti-VEGFR inhibitor)
  • Shanghai, Shanghai, China
    Ninth People's Hospital, Shanghai Jiao Tong University School of
Oct 8, 2022

Adenocarcinoma of Esophagogastric Junction Trial in Beijing (neoadjuvant Radiation plus SOX and PD-1 antibody)

Not yet recruiting
  • Adenocarcinoma of Esophagogastric Junction
  • neoadjuvant Radiation plus SOX and PD-1 antibody
  • Beijing, Beijing, China
    Peking University People's Hospital
Aug 15, 2022

Locally Advanced Rectal Cancer Trial in Beijing (Long-course chemoradiation, with Tislelizumab (PD-1 inhibitor), Long-course

Recruiting
  • Locally Advanced Rectal Cancer
  • Long-course chemoradiation, with Tislelizumab (PD-1 inhibitor)
  • Long-course chemoradiation, without Tislelizumab (PD-1 inhibitor)
  • Beijing, Beijing, China
    Beijing Friendship Hospital, Capital Medical University
Apr 25, 2023

Locally Advanced Esophageal Carcinoma Trial in Nanjing (Neoadjuvant Chemotherapy, Neoadjuvant Toripalimab, Short Course

Recruiting
  • Locally Advanced Esophageal Carcinoma
  • Neoadjuvant Chemotherapy
  • +2 more
  • Nanjing, Jiangsu, China
    Jiangsu Cancer Hospital /Jiangsu Institute of Cancer Research
Jun 21, 2022

Bevacizumab Combined With PD-1 Monoclonal Antibody in

Not yet recruiting
  • Colorectal Cancer
  • Bevacizumab Combined With PD-1 Monoclonal Antibody
  • (no location specified)
Nov 8, 2023

Hepatocellular Carcinoma Trial in Beijing (Sintilimab, Lenvatinib, radiotherapy)

Recruiting
  • Hepatocellular Carcinoma
  • Beijing, Beijing, China
    Beijing Tsinghua Changgung Hospital
Jan 5, 2023

Esophageal Carcinoma, Neoadjuvant Immunotherapy Trial in Beijing (PD-1 blockade, Albumin paclitaxel, Carboplatin/Nedaplatin)

Recruiting
  • Esophageal Carcinoma
  • Neoadjuvant Immunotherapy
  • PD-1 blockade
  • +2 more
  • Beijing, Beijing, China
    Qin li
Mar 8, 2023

Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and

Not yet recruiting
  • Colorectal Neoplasms
  • Beijing, Xicheng Dis, China
    Beijing Friendship Hospital, Capital medical University
Sep 5, 2023